Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Mar;21(2):162-70.
doi: 10.1097/CCO.0b013e328324bc04.

Stem cell transplantation for multiple myeloma

Shaji Kumar  1
Affiliations
Review

Stem cell transplantation for multiple myeloma

Shaji Kumar. Curr Opin Oncol. 2009 Mar.

Abstract

Purpose of review: Autologous stem cell transplantation (SCT) has been an integral part of the management of multiple myeloma, especially for younger patients. During the past decade, several highly effective therapies have become available for treatment of myeloma, raising questions about the role of SCT for its management. This review focuses on recent findings in the context of previous studies demonstrating a benefit for SCT compared with conventional therapies.

Recent findings: Recent clinical trials have primarily focused on improving patient outcome by integrating the novel agents into various stages of myeloma therapy, including initial therapy resulting in improvement of disease control at the time of SCT, incorporation into conditioning regimens and finally, using maintenance approaches to prolong the response from SCT. In addition, recent trials also have demonstrated a potential role for tandem SCT in selected patients. However, the role of allogeneic SCT still remains to be better defined.

Summary: Patients with myeloma have more effective choices for therapy today and better outcome. Recent and ongoing trials will allow better selection of therapy, preferably in an individualized fashion, potentially translating into prolonged survival.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Decision tree for treatment approach in patients with newly diagnosed myeloma considered eligible for autologous stem cell transplantation
ASCT, autologous stem cell transplantation; FISH, fluorescence in-situ hybridization; VGPR, very good partial response.
See this image and copyright information in PMC

References

    1. Attal M, Harousseau JL, Stoppa AM, et al. Intergroupe Francais du Myelome. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335:91–97. - PubMed
    1. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–1883. - PubMed
    1. Rajkumar SV, Blood E, Vesole DH, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431–436. - PubMed
    1. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487–2498. - PubMed

    1. Rajkumar SV, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood. 2007;110:74. ASH Annual Meeting Abstracts.. This trial brought about a paradigm change in the treatment of myeloma by demonstrating better outcome with lower doses of steroids despite a lowering of response rates. In addition, the 2-year survival was one of the highest seen with any drug therapy for myeloma.